In a study designed to see if doctors who are told the exact price of expensive medical tests like magnetic resonance imaging (MRI) in advance would order fewer of them, Johns Hopkins researchers got their answer: No.


Varian Medical Systems has received a U.S. Food and Drug Administration (FDA)- 510(k) clearance for the latest version of its Vitesse real time planning for HDR brachytherapy which is used to plan and perform high-dose-rate (HDR), ultrasound-guided brachytherapy treatments for prostate cancer.

Avreo announced the release of Version 7.4 for preview at HIMSS 2013. Version 7.4 enhancements include voice recognition improvements such as voice command shortcuts, advanced report template management and new voice recognition editor workflow to offer interpreting physicians the option to send voice recognition reports to an editor for final review prior to distribution.

Synapse Cardiovascular 5.0


Sports-related concussions and mild traumatic brain injuries have grabbed headlines in recent months, as the long-term damage they can cause becomes increasingly evident among both current and former athletes. The Centers for Disease Control and Prevention estimates that millions of these injuries occur each year.


The study finds that in several countries in Western Europe there are too few radiotherapy machines to ensure that cancer patients in need of radiotherapy receive treatment. For instance, in Italy around 16 percent of need is unmet, in Portugal 19 percent, Austria 20 percent and the UK and Germany 21 percent. However, the authors caution that these apparent gaps in treatment supply may be compensated by more efficient organization of radiotherapy provision.

Elekta and Philips Healthcare announced The University of Texas MD Anderson Cancer Center (Houston, Texas) has signed an agreement to join a research group to advance the development of an innovative image-guided treatment technology for cancer care. The technology merges radiation therapy and magnetic resonance imaging (MRI) technology in a single system. MD Anderson is the second member of the research consortium, which will comprise leading radiation oncology centers and clinicians, and already includes the University Medical Center Utrecht (the Netherlands).

Subscribe Now